Clinical trials: Immunoglobulin Prophylaxis
Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer
Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)
Anti-EGFR (Epidermal Growth Factor Receptor) therapies, namely cetuximab and panitumumab, have become standards in the management of metastatic colorectal and head and neck cancers.
- Trial name
- OPTIMAG (NCT03146338)
- Testing
- Magnesium-rich mineral water (Rozana)
- Where
- 12 sites in France
- Volunteers
- 106 people
- Sponsor
- Weprom
HIV
A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
Background: HIV is a serious disease with no cure or vaccine to prevent it. Using antibodies could be a way to prevent HIV infection. Antibodies are made by the human body to fight germs.
- Trial name
- VRC 611 (NCT04408963)
- Testing
- VRC-HIVMAB0102-00-AB
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Meningococcal Infection
Kinetics of B Cell Response in Infants Menjugate Vaccination
Kinetics of B cell response in infants Menjugate vaccination
- Trial name
- NCT00310700
- Testing
- Meningococcal C conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis
Metastatic Melanoma
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and…
- Trial name
- NCT05034536
- Testing
- Pembrolizumab, Infliximab, Relatlimab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Healthy Adult Immune Response
Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults
Background: Human immunodeficiency virus (HIV) infection is a serious disease. There is no cure or vaccine to prevent infection. Using antibodies might be a good way to treat or prevent HIV.
- Trial name
- NCT03565315
- Testing
- VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HBV
Prevention for Mother-to-infant Transmission of HBV
In this study, HBV-infected pregnant women were divided into two groups, those who received and those who did not receive hepatitis B immunoglobulin (HBIG) during pregnancy.
- Trial name
- NCT02312531
- Testing
- Hepatitis B immunoglobulin
- Volunteers
- 28 people
- Sponsor
- Xi'an Jiaotong University
Allografts, Rejection; Transplant, Kidney
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased…
- Conditions
- Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
- Trial name
- NCT04046549
- Testing
- Belatacept, VIB4920, Thymoglobulin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Amgen
Graft Versus Host Disease, Hematologic Neoplasms
Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT
Acute graft-versus-host disease remains a major complication after haploidentical hematopoietic stem cell transplantation. Methotrexate is commonly used as part of graft-versus-host disease prophylaxis, but it may be associated…
- Trial name
- NCT07689630
- Testing
- Methotrexate, Anti-CD25 Monoclonal Antibody
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rabies Infection
Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
Demonstrate non-inferiority of the immune response between new versus the currently recommended intradermal regimens of rabies vaccine when administered with or without rabies immunoglobulins in healthy subjects ≥ 1 years of age.
- Trial name
- NCT02177032
- Testing
- Rabies vaccine, Rabies vaccines + Rabies immunoglobulins
- Where
- 6 sites in Philippines, Thailand
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- Novartis
Rabies, Rabies Human
Survey of Human Rabies Immune Globulin Safety in Children
This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States.
- Conditions
- Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
- Trial name
- NCT05382650
- Testing
- Human rabies immune globulin 300 IU/mL
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- The Methodist Hospital Research Institute
Rabies, Communicable Disease
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
This is a Phase 3, blinded, randomized study of SYN023 compared to a China licensed Human Rabies Immunoglobulin (a Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis…
- Conditions
- Rabies, Communicable Disease, Virus Diseases, Rhabdoviridae Infections
- Trial name
- NCT04644484
- Testing
- SYN023, Human Rabies Immune Globulin (HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 23 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Mountain Sickness
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
Acute mountain sickness (AMS) is a common condition that can occur when healthy people travel quickly to high altitude. Typical symptoms include headache, nausea, tiredness, dizziness, and poor sleep.
- Trial name
- NCT07653516
- Testing
- Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Human Immunodeficiency Virus
3BNC117 and 10-1074 in HIV Uninfected Adults
This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human…
- Trial name
- NCT02824536
- Testing
- 3BNC117, 10-1074
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
COVID-19
Study of VYD2311 for the Prevention of COVID-19
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19.
- Trial name
- DECLARATION (NCT07298434)
- Testing
- VYD2311-SD, VYD2311-MD
- Where
- 20 sites in United States
- Volunteers
- 1,770 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.
Prevention of Meningococcal Infection
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children
- Trial name
- NCT00311415
- Testing
- Meningococcal C conjugate vaccine
- Where
- 2 sites in Germany, Poland
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Kidney Transplant Rejection
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
- Trial name
- NCT05983770
- Testing
- AT-1501, Tacrolimus
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Eledon Pharmaceuticals
Kidney Transplant Rejection
Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients
The aim of the present study is to evaluate the superiority of photopheresis in combination with the standard immunosuppression vs standard immunosuppression alone for the prevention of acute rejection in highly sensitized kidney…
- Trial name
- NCT04414735
- Testing
- Extracorporeal Photopheresis
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Rabies
Rabies Immunization Concomitant With JEV in Children
Background. The World Health Organization recommends pre-exposure vaccination (PreP) to protect children living in canine rabies endemic countries.
- Trial name
- NCT00703521
- Testing
- Rabies vaccine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Rabies
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2.
- Trial name
- KAMRAB-003 (NCT02040090)
- Testing
- Active rabies vaccine (US-FDA approved)
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Kamada, Ltd.